Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.31 -0.19 (-1.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Sarepta Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Sarepta Therapeutics's Earnings Outlook ↗

February 28, 2022

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership ↗

February 01, 2022

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to

Via Benzinga

Analyst Ratings For Sarepta Therapeutics ↗

January 18, 2022

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 14, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate ↗

January 13, 2022

Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

Expert Ratings For Sarepta Therapeutics ↗

December 09, 2021

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th...

Via Benzinga

Analyst Ratings For Sarepta Therapeutics ↗

November 04, 2021

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...

Via Benzinga

Expert Ratings For Sarepta Therapeutics ↗

October 15, 2021

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

January 05, 2022

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗

December 09, 2021

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 ↗

November 05, 2021

Upgrades For IGM Biosciences Inc (NASDAQ:

Via Benzinga

Why Sarepta Therapeutics Shares Dropped More Than 16% This Week ↗

November 04, 2021

The biotech stock fell a little more than $72 since its close last Friday.

Via The Motley Fool

Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

SRPT earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Is This Beaten Down Biotech a Bad News Buy? ↗

October 20, 2021

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

Via The Motley Fool

Why Sarepta Therapeutics Fell 14.7% This Week ↗

October 14, 2021

Investors were unimpressed by the company's clinical and financial news.

Via The Motley Fool

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

Why Sarepta Therapeutics Tumbled Today ↗

October 13, 2021

Investors weren't wowed by a company update, or by news of a fresh stock issue.

Via The Motley Fool

40 Stocks Moving In Wednesday's Mid-Day Session ↗

October 13, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes ↗

October 13, 2021

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are...

Via Benzinga

Topics Economy Stocks

5 Stocks To Watch For October 13, 2021 ↗

October 13, 2021

Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue...

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today